Evaluation of Combined 177 Lu-DOTA-8-AOC-BBN (7-14)NH 2 GRP Receptor-Targeted Radiotherapy and Chemotherapy in PC-3 Human Prostate Tumor Cell Xenografted SCID Mice
- 1 April 2006
- journal article
- research article
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 21 (2) , 155-166
Abstract
The focus of this study was to evaluate the therapeutic benefit of combined gastrin-releasing peptide (GRP) receptor-targeted radiotherapy (TRT) with chemotherapy, using the PC-3 xenograft severe combined immunodeficiency (SCID) mouse model. 177Lu-DOTA-8-AOC-BBN(7-14)NH2 is a radiotherapeutic peptide that specifically targets the gastrin-releasing peptide receptor overexpressed on primary and metastatic prostate cancer. The chemotherapeutic agents, docetaxel and estramustine, were administered as single agents or in combination with the receptor-targeted radiotherapeutic agent. Combination receptor TRT/chemotherapy studies were begun 21 days postxenografting and were conducted as multiple-dose trials. The GRP receptor TRT agent was administered every 14 days, and single and combination chemotherapy dose regimens were given weekly. Tumor size, body weight, and body condition score were evaluated twice-weekly and a hematology profile once-weekly. Therapy study tumor volumes were evaluated by way of a repeated measures analysis of variance (ANOVA). Tumor volume measurements at 12 days postdose administration demonstrated a statistically significant (two-tailed P-value 177Lu-DOTA-8-AOC-BBN(7-14)NH2, used either alone or in combination with conventional chemotherapy, can suppress the growth of androgen- independent prostate cancer (AIPC).Keywords
This publication has 49 references indexed in Scilit:
- A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate CancerOncology, 2004
- Peptide Receptor Radionuclide TherapyAnnals of the New York Academy of Sciences, 2004
- Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583)Journal of Clinical Oncology, 2004
- Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findingsSeminars in Nuclear Medicine, 2002
- Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostateSeminars in Oncology, 2001
- Weekly docetaxel and estramustine in patients with hormonerefractory prostate cancerSeminars in Oncology, 2001
- Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancerSeminars in Oncology, 2001
- Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancerSeminars in Oncology, 2001
- Radioiodinated estramustine phosphate and estramustine binding protein Antibody accumulate in the prostate of a mouseThe Prostate, 1997
- MOLMOL: A program for display and analysis of macromolecular structuresJournal of Molecular Graphics, 1996